JP2024506909A - Hpk1アンタゴニスト及びその使用 - Google Patents
Hpk1アンタゴニスト及びその使用 Download PDFInfo
- Publication number
- JP2024506909A JP2024506909A JP2023548686A JP2023548686A JP2024506909A JP 2024506909 A JP2024506909 A JP 2024506909A JP 2023548686 A JP2023548686 A JP 2023548686A JP 2023548686 A JP2023548686 A JP 2023548686A JP 2024506909 A JP2024506909 A JP 2024506909A
- Authority
- JP
- Japan
- Prior art keywords
- nitrogen
- sulfur
- oxygen
- compound
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163148857P | 2021-02-12 | 2021-02-12 | |
| US63/148,857 | 2021-02-12 | ||
| PCT/US2022/070627 WO2022174253A1 (en) | 2021-02-12 | 2022-02-11 | Hpk1 antagonists and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024506909A true JP2024506909A (ja) | 2024-02-15 |
| JP2024506909A5 JP2024506909A5 (cg-RX-API-DMAC7.html) | 2025-02-18 |
Family
ID=82837982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023548686A Pending JP2024506909A (ja) | 2021-02-12 | 2022-02-11 | Hpk1アンタゴニスト及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12252488B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4291235A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024506909A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117120090A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022174253A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3873608A1 (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| EP4371987B9 (en) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| CN116063329A (zh) * | 2021-10-29 | 2023-05-05 | 北京望实智慧科技有限公司 | Hpk1抑制剂、制备方法及其用途 |
| WO2023193759A1 (en) * | 2022-04-07 | 2023-10-12 | Insilico Medicine Ip Limited | Hpk1 antagonists and uses thereof |
| GB202216324D0 (en) * | 2022-11-02 | 2022-12-14 | Cerevance Ltd | Novel compounds |
| TW202434215A (zh) * | 2022-12-26 | 2024-09-01 | 香港商英矽智能科技知識產權有限公司 | 螺環hpk1拮抗劑及其用途 |
| US11932649B1 (en) | 2023-08-17 | 2024-03-19 | King Faisal University | 5-(3-substituted phenyl)-pyrimido[4,5-d]pyrimidine-2,4,7(1H,3H,8H)-trione derivatives as anticancer agents |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008105515A1 (ja) * | 2007-02-28 | 2008-09-04 | Taisho Pharmaceutical Co., Ltd. | 新規なヒドロキサム酸誘導体 |
| JP2011510990A (ja) * | 2008-02-01 | 2011-04-07 | アイアールエム・リミテッド・ライアビリティ・カンパニー | キナーゼ阻害剤としての化合物および組成物 |
| JP2013500972A (ja) * | 2009-07-30 | 2013-01-10 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Sykキナーゼ阻害剤としての2,7−ナフチリジン−1−オン誘導体 |
| JP2013501002A (ja) * | 2009-07-30 | 2013-01-10 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Sykキナーゼ阻害剤としての化合物および組成物 |
| JP2014502976A (ja) * | 2011-01-21 | 2014-02-06 | アッヴィ・インコーポレイテッド | Alkの二環式阻害剤 |
| JP2020515603A (ja) * | 2017-03-30 | 2020-05-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Hpk1阻害剤としてのイソキノリン |
| WO2020106307A1 (en) * | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks |
| WO2020111087A1 (ja) * | 2018-11-28 | 2020-06-04 | 武田薬品工業株式会社 | 複素環化合物 |
| CN111961035A (zh) * | 2019-05-20 | 2020-11-20 | 南京科技职业学院 | 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用 |
| WO2021000935A1 (en) * | 2019-07-04 | 2021-01-07 | Qilu Regor Therapeutics Inc. | Hpk1 inhibitors and uses thereof |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2475569A (en) | 1944-02-07 | 1949-07-05 | American Cyanamid Co | Substituted pyridine compound |
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
| OA12118A (en) | 1999-12-10 | 2006-05-04 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds. |
| UA72612C2 (en) | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
| KR100833371B1 (ko) | 2001-04-27 | 2008-05-28 | 젠야쿠코교가부시키가이샤 | 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제 |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| AU2003211384B2 (en) * | 2002-02-21 | 2008-12-11 | Asahi Kasei Pharma Corporation | Substituted phenylalkanoic acid derivative and use thereof |
| MXPA05001766A (es) | 2002-08-14 | 2005-08-19 | Atugen Ag | Uso de proteina quinasa n beta. |
| WO2004089925A1 (en) | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| US7129260B2 (en) | 2003-06-02 | 2006-10-31 | Abbott Laboratories | Isoindolinone kinase inhibitors |
| WO2005007623A2 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| LT2612862T (lt) | 2004-05-13 | 2017-01-25 | Icos Corporation | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール,インク. | Gitr結合分子およびその使用 |
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| HRP20140975T1 (hr) | 2005-10-07 | 2014-11-21 | Exelixis, Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze |
| CA2627892A1 (en) | 2005-11-01 | 2007-05-10 | Janssen Pharmaceutica N.V. | Substituted dihydroisoindolones as allosteric modulators of glucokinase |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| KR101533461B1 (ko) | 2006-04-26 | 2015-07-02 | 에프. 호프만-라 로슈 아게 | Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체 |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| JPWO2008047831A1 (ja) | 2006-10-17 | 2010-02-25 | 協和発酵キリン株式会社 | Jak阻害剤 |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| KR20100015857A (ko) * | 2007-04-23 | 2010-02-12 | 노파르티스 아게 | S1p 수용체 조절 활성을 갖는 프탈라진 및 이소퀴놀린 유도체 |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| GB0724342D0 (en) | 2007-12-13 | 2008-01-30 | Prolysis Ltd | Anitbacterial compositions |
| MY165582A (en) | 2008-03-11 | 2018-04-05 | Incyte Holdings Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| EP2296789A1 (fr) | 2008-05-29 | 2011-03-23 | Saint-Gobain Centre de Recherches et d'Etudes Européen | Structure en nid d'abeille a base de titanate d'aluminium |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| IN2015DN02826A (cg-RX-API-DMAC7.html) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| DK2510010T3 (en) | 2009-12-10 | 2015-12-14 | Hoffmann La Roche | Antibodies that bind to human CSF1R extracellular domain 4 and their use |
| EP2516434B1 (en) | 2009-12-23 | 2015-05-27 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones as syk inhibitors |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| US8314120B2 (en) | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
| EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| NO2694640T3 (cg-RX-API-DMAC7.html) | 2011-04-15 | 2018-03-17 | ||
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| TW201329067A (zh) | 2011-12-08 | 2013-07-16 | Amgen Inc | 作為gka活化劑之脲化合物 |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2014140739A (ru) * | 2012-03-09 | 2016-04-27 | Лексикон Фармасьютикалз, Инк. | Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| EP2922841B8 (en) | 2012-11-08 | 2017-08-02 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| HRP20220766T1 (hr) | 2012-11-08 | 2022-09-16 | Bristol-Myers Squibb Company | Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora |
| ES2702126T3 (es) | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| US9340540B2 (en) | 2014-02-28 | 2016-05-17 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| WO2016101119A1 (en) | 2014-12-23 | 2016-06-30 | Merck Sharp & Dohme Corp. | Fused heteroaryl derivatives as orexin receptor antagonists |
| RS61919B1 (sr) | 2015-06-25 | 2021-06-30 | Univ Health Network | Inhibitori hpk1 i postupci za njihovo korišćenje |
| CN108699077B (zh) | 2016-01-15 | 2021-03-02 | 英安塔制药有限公司 | 作为rsv抑制剂的杂环化合物 |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| WO2018109607A1 (en) | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| CN110678466B (zh) | 2017-03-30 | 2023-01-31 | 豪夫迈·罗氏有限公司 | 作为hpk1抑制剂的二氮杂萘类 |
| WO2019070742A1 (en) * | 2017-10-03 | 2019-04-11 | Sidecar Therapeutics, Inc. | APOPTOSIS SIGNAL REGULATION KINASE 1 (ASK 1) INHIBITORS COMPOUNDS |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| CA3103304A1 (en) * | 2018-06-15 | 2019-12-19 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| CA3112510A1 (en) | 2018-10-29 | 2020-05-07 | Boehringer Ingelheim International Gmbh | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
| US12215105B2 (en) | 2019-09-13 | 2025-02-04 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
-
2022
- 2022-02-11 WO PCT/US2022/070627 patent/WO2022174253A1/en not_active Ceased
- 2022-02-11 US US17/650,732 patent/US12252488B2/en active Active
- 2022-02-11 CN CN202280027804.3A patent/CN117120090A/zh active Pending
- 2022-02-11 EP EP22753561.4A patent/EP4291235A4/en active Pending
- 2022-02-11 JP JP2023548686A patent/JP2024506909A/ja active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008105515A1 (ja) * | 2007-02-28 | 2008-09-04 | Taisho Pharmaceutical Co., Ltd. | 新規なヒドロキサム酸誘導体 |
| JP2011510990A (ja) * | 2008-02-01 | 2011-04-07 | アイアールエム・リミテッド・ライアビリティ・カンパニー | キナーゼ阻害剤としての化合物および組成物 |
| JP2013500972A (ja) * | 2009-07-30 | 2013-01-10 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Sykキナーゼ阻害剤としての2,7−ナフチリジン−1−オン誘導体 |
| JP2013501002A (ja) * | 2009-07-30 | 2013-01-10 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Sykキナーゼ阻害剤としての化合物および組成物 |
| JP2014502976A (ja) * | 2011-01-21 | 2014-02-06 | アッヴィ・インコーポレイテッド | Alkの二環式阻害剤 |
| JP2020515603A (ja) * | 2017-03-30 | 2020-05-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Hpk1阻害剤としてのイソキノリン |
| WO2020106307A1 (en) * | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks |
| WO2020111087A1 (ja) * | 2018-11-28 | 2020-06-04 | 武田薬品工業株式会社 | 複素環化合物 |
| CN111961035A (zh) * | 2019-05-20 | 2020-11-20 | 南京科技职业学院 | 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用 |
| WO2021000935A1 (en) * | 2019-07-04 | 2021-01-07 | Qilu Regor Therapeutics Inc. | Hpk1 inhibitors and uses thereof |
Non-Patent Citations (7)
| Title |
|---|
| COMPAGNON, PAUL LOUIS ET AL.: "Pyridines. XIV. Acylation of pyridyl lithioenamidines. Synthesis of pyridyl N-(acyl)enamidines an", BULLETIN DES SOCIETES CHIMIQUES BELGES, vol. 95(1), JPN7025005284, 1986, pages 57 - 64, ISSN: 0005746913 * |
| REGISTRY (STN) [ONLINE], JPN7025005285, ISSN: 0005746914 * |
| REGISTRY (STN) [ONLINE], JPN7025005286, ISSN: 0005746915 * |
| REGISTRY (STN) [ONLINE], JPN7025005287, ISSN: 0005746916 * |
| REGISTRY (STN) [ONLINE], JPN7025005288, ISSN: 0005746917 * |
| REGISTRY (STN) [ONLINE], JPN7025005289, ISSN: 0005746918 * |
| SOLIMAN, A. Y. ET AL.: "Nitriles in heterocyclic synthesis: studies on ethyl 3-amino-4,4-dicyano-3-butenoate", REVUE ROUMAINE DE CHIMIE, vol. 38(9), JPN7025005283, 1993, pages 1097 - 104, ISSN: 0005746912 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022174253A1 (en) | 2022-08-18 |
| EP4291235A4 (en) | 2025-01-08 |
| US20230096641A1 (en) | 2023-03-30 |
| CN117120090A (zh) | 2023-11-24 |
| US12252488B2 (en) | 2025-03-18 |
| EP4291235A1 (en) | 2023-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7811542B2 (ja) | Hpk1アンタゴニストおよびその使用 | |
| JP7498200B2 (ja) | Tyk2阻害剤およびその使用 | |
| WO2021127190A1 (en) | Irak degraders and uses thereof | |
| WO2020264499A1 (en) | Irak degraders and uses thereof | |
| EP4076524A2 (en) | Irak degraders and uses thereof | |
| JP7699052B2 (ja) | Tyk2阻害剤およびその使用 | |
| AU2019360941A1 (en) | TYK2 inhibitors and uses thereof | |
| EP4291235A1 (en) | Hpk1 antagonists and uses thereof | |
| US11926625B2 (en) | HPK1 antagonists and uses thereof | |
| EP4405359A2 (en) | Mdm2 degraders and uses thereof | |
| WO2023278759A1 (en) | Mk2 degraders and uses thereof | |
| WO2023015199A1 (en) | Hpk1 antagonists and uses thereof | |
| JP2024513011A (ja) | Hpk1アンタゴニスト及びその使用 | |
| HK40055822B (en) | Tyk2 inhibitors and uses thereof | |
| HK40055822A (en) | Tyk2 inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250207 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250207 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20251113 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251204 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260525 |